AF mortality and morbidity high at 1 year despite good anticoagulant use

August 31, 2014

Barcelona, Spain - Sunday 31 August 2014: Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry. The findings were presented for the first time at ESC Congress 2014 today by registry chairperson Professor Gregory Lip (Birmingham, UK).

Professor Lip said: "This is the first contemporary, ESC sponsored registry focused on management practices of European cardiologists conducted since the ESC guidelines on AF were published in 2010 and 2012(1,2). The results show us the impact of these ESC guidelines."

The Atrial Fibrillation General Pilot Registry is part of the ESC's EORP programme (3) and includes over 3 000 patients in 9 countries. Data are being collected on treatment and outcomes of consecutive patients with AF presenting to European cardiologists.

The one year follow up results reveal that more than 80% of AF patients who are at risk of embolism according to the CHA2DS2-VASc score receive appropriate anticoagulation. But one year mortality is still high (approximately 6%), of which most are cardiovascular deaths. Approximately 20% of patients taking anticoagulants required a change in treatment at one year. Some patients taking warfarin switched to a non-vitamin K antagonist oral anticoagulant (NOAC), while some initially on a NOAC changed to a different antithrombotic drug. A small minority were started on aspirin despite the guidelines and little evidence for the efficacy and safety of aspirin.

Professor Lip said: "The results show that many European cardiologists prescribe oral anticoagulation for their patients with AF and this is encouraging. But we shouldn't rest on our laurels given that these patients still experience high mortality and morbidity at one year. And we need more information on why so many patients are changing the type of anticoagulation they use."

The researchers compared which risk factors present at baseline predicted stroke or mortality at one year. They found that the main predictors of stroke or mortality were age, heart failure, previous transient ischaemic attack (TIA), kidney disease, malignancy and previous bleeding events. The highest predictors of mortality alone were kidney disease, diuretic use, age, malignancy, previous TIA, previous bleeding and chronic obstructive pulmonary disease (COPD). Statins were protective against mortality.

Professor Lip said: "Interestingly, we found that statins reduced mortality by about one-third. On the other hand, diuretics increased mortality by about 70%."

Other findings from the one year follow up were: Professor Lip concluded: "These one year results are generally encouraging and uptake of ESC guidelines has been reasonably good. There has been a focus on patient centred and symptom directed management, and there has been an improvement in anticoagulation with increasing use of the CHA2DS2-VASc score. However we still need to pay attention to the high mortality and morbidity of AF patients and the tendency of some cardiologists to change the type of anticoagulation after one year."

The Atrial Fibrillation General Pilot Registry is ongoing and further results will be reported at years two and three. The Atrial Fibrillation General Long Term Registry began in October 2013 and is currently recruiting from ESC member countries.

European Society of Cardiology

Related Kidney Disease Articles from Brightsurf:

Waistline matters in kidney disease
Does fat matter in kidney disease? The investigators found that all measures of higher abdominal fat content (including visceral fat, liver fat, or subcutaneous fat) and slower walk times were associated with increased levels of cardiometabolic risk factors in adults with non-dialysis dependent kidney disease.

Reducing urinary protein for patients with rare kidney disease slows kidney decline
New findings show that reducing the amount of protein in the urine of patients with focal segmental glomerulosclerosis can significantly slow declines in kidney function and extend time before patients' kidneys fail.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.

Genes tell a story about diabetic kidney disease
Studying Finnish genes leads to unique revelations about the development of a serious complication of diabetes, and informs an ongoing genomic study of a Singaporean cohort as part of Singapore's Diabetes Study in Nephropathy and other Microvascular Complications (DYNAMO).

New study provides insight into chronic kidney disease
Researchers have further analyzed a known signaling pathway they believe brings them one step closer to understanding the complex physiology of patients with chronic kidney disease (CKD), which might provide a path to new treatment options.

Predicting risk of chronic kidney disease
Data from about 5 million people (with and without diabetes) in 28 countries were used to develop equations to help identify people at increased five-year risk of chronic kidney disease, defined as reduced estimated glomerular filtration rate (eGFR).

A healthy diet may help prevent kidney disease
In an analysis of published studies, a healthy dietary pattern was associated with a 30% lower incidence of chronic kidney disease.

Is kidney failure a man's disease?
A new analysis of the ERA-EDTA Registry [1] reveals a striking gender difference in the incidence and prevalence of end-stage renal disease.

Chronic kidney disease: Everyone's concern
850 million people worldwide are affected by kidney disease. This worrying figure was published last June.

Read More: Kidney Disease News and Kidney Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to